About TOM1-like protein 1
TOM1-like protein 1 (TOM1L1) is a protein
from Homo sapiens identified by UniProt accession
O75674, 476 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | TOM1-like protein 1 |
|---|
| UniProt accession | O75674 |
|---|
| Gene | TOM1L1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 476 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (47)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.30
- body mass index · score 0.30
- lean body mass · score 0.27
- fat body mass · score 0.27
- body weight · score 0.26
- waist circumference · score 0.19
- hip circumference · score 0.19
- Hernia · score 0.16
- monoclonal gammopathy · score 0.15
- breast carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75674-F1 | alphafold | PREDICTED | 67.54 | — |
Amino-acid sequence (476 residues)
MAFGKSHRDP YATSVGHLIE KATFAGVQTE DWGQFMHICD IINTTQDGPK DAVKALKKRI SKNYNHKEIQ LTLSLIDMCV QNCGPSFQSL IVKKEFVKEN LVKLLNPRYN LPLDIQNRIL NFIKTWSQGF PGGVDVSEVK EVYLDLVKKG VQFPPSEAEA ETARQETAQI SSNPPTSVPT APALSSVIAP KNSTVTLVPE QIGKLHSELD MVKMNVRVMS AILMENTPGS ENHEDIELLQ KLYKTGREMQ ERIMDLLVVV ENEDVTVELI QVNEDLNNAI LGYERFTRNQ QRILEQNKNQ KEATNTTSEP SAPSQDLLDL SPSPRMPRAT LGELNTMNNQ LSGLNFSLPS SDVTNNLKPS LHPQMNLLAL ENTEIPPFAQ RTSQNLTSSH AYDNFLEHSN SVFLQPVSLQ TIAAAPSNQS LPPLPSNHPA MTKSDLQPPN YYEVMEFDPL APAVTTEAIY EEIDAHQHKG AQNDGD
Explore TOM1-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets